Flossbach Von Storch SE Acquires New Stake in IDEXX Laboratories, Inc. $IDXX

Flossbach Von Storch SE bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 17,270 shares of the company’s stock, valued at approximately $9,092,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Harbour Investments Inc. grew its position in IDEXX Laboratories by 13.3% in the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after acquiring an additional 16 shares in the last quarter. Pinnacle Associates Ltd. lifted its position in shares of IDEXX Laboratories by 1.5% during the fourth quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock worth $830,000 after purchasing an additional 18 shares in the last quarter. Triad Wealth Partners LLC boosted its stake in shares of IDEXX Laboratories by 3.1% in the first quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock valued at $337,000 after purchasing an additional 18 shares during the period. Advisory Services Network LLC boosted its stake in shares of IDEXX Laboratories by 2.5% in the fourth quarter. Advisory Services Network LLC now owns 752 shares of the company’s stock valued at $509,000 after purchasing an additional 18 shares during the period. Finally, KCM Investment Advisors LLC grew its holdings in shares of IDEXX Laboratories by 5.3% in the fourth quarter. KCM Investment Advisors LLC now owns 377 shares of the company’s stock valued at $255,000 after purchasing an additional 19 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on IDXX shares. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. UBS Group upped their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup lifted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Finally, Barclays lowered their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Trading Up 1.6%

Shares of NASDAQ:IDXX opened at $562.20 on Thursday. IDEXX Laboratories, Inc. has a 52 week low of $518.55 and a 52 week high of $769.98. The company’s 50 day moving average is $560.33 and its two-hundred day moving average is $577.89. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company has a market cap of $44.29 billion, a PE ratio of 39.54, a P/E/G ratio of 2.95 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the company earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.